The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 receptor agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. While https://mariahqvii306525.wikidirective.com/8035766/glp_3_retatrutide_a_comparative_analysis